Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH

Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH

Source: 
Fierce Biotech
snippet: 

Shares of cell therapy developer Fate Therapeutics shot up more than 8% Friday morning to $15.31 after the company announced that the FDA accepted its IND application for a cell therapy it’s developing called FT500 to treat advanced solid tumors.